SH
Shukra Pharmaceuticals Ltd (SHUKRAMED)
₹84.16
Mkt cap
₹3,724 Cr
P/E ratio
84.00
P/B
31.29
Div yield
0.01%
ROE
28.90%
ROCE
37.00%
EPS (TTM)
₹1.00
Book value
₹3
52W range
40–85
Sector
Healthcare
Price history
Previous close
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing [1]
NSE SHUKRAMEDBSE 524632
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−0.75% from high₹84
₹40+110.08% from low₹85
Current
₹84.16
Prev close
₹84.20
Day
−0.05%
Price performance
1D
−0.05%
1W
+2.35%
1M
+30.56%
3M
+91.01%
6M
—
1Y
—
YTD
+103.19%
Financials
Revenue, profit & margin
P/E ratio
84.0×
SHUKRAMED is 159% above the sector median of 32.5×
SHUKRAMED84.0×
Sector median32.5×
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 | 44 | |
| YoY Sales growth | +562% | +721% | -76% | -84% | -77% | +270% | -52% | +336% | +652% | |||||
| Expenses | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 4 | 26 | |
| Operating Profit | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | -0 | 27 | 1 | 19 | 19 | |
| OPM % | 21% | 51% | 41% | 25% | 12% | 37% | 55% | 24% | -7% | 69% | 11% | 81% | 42% | |
| Other Income | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Profit before tax | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 18 | 18 | |
| Tax % | -0% | 1% | 24% | 41% | 39% | 23% | 29% | 26% | -1,090% | 24% | 553% | 29% | 29% | |
| Net Profit | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20 | -2 | 13 | 13 | |
| EPS in Rs | 0.11 | 0.22 | 0.09 | 0.01 | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.29 | 0.29 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202651.16%Promoter
Promoters51.16%0.21
FIIs0.43%0.43
DIIs0.21%0.10
Public48.20%0.73
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Shukra Pharma. | ₹84.16 | 84.05 | 3,724 | 0.01% | 13 | +434.03% | 44 | +651.70% | 36.98% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Change of Company Name 16 Nov - NSE approved name change to Shukra Medtech Limited and symbol SHUKRAMED, effective November 20, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 6 NovAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 5 Nov - Q2 FY27 revenue rose 652% to Rs44.20 crore; net profit increased to Rs16.01 crore.Reg 32 4 Nov - No deviation in utilization of Rs 10.46 crore preferential warrant proceeds for Q2 FY27.Unaudited Financial Results For The Quarter Ended 30Th September 2026 4 Nov - Board approved Q2/H1 FY27 results; name changed to Shukra Medtech, warrants converted.






